The second‐generation curcumin analogue RL71 elicits G2/M cell cycle arrest and apoptosis in canine osteosarcoma cells
Authors:
Open Access
- 12 July 2023
- journal article
- research article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 21 (4) , 595-604
Abstract
Canine osteosarcoma is an aggressive cancer, comprising 85% of canine bone neoplasms. Current treatment practices of surgery and chemotherapy increase 1‐year survival by only 45%. The curcumin analogue RL71, has demonstrated potent in vitro and in vivo efficacy in several models of human breast cancer through increased apoptosis and cell cycle arrest. Thus, the present study aimed to investigate efficacy of curcumin analogues in two canine osteosarcoma cell lines. Osteosarcoma cell viability was assessed using the sulforhodamine B assay and mechanisms of action were determined by analysing the levels of cell cycle and apoptotic regulatory proteins via Western blotting. Further evidence was obtained using flow cytometry to detect cell cycle distribution and the number of apoptotic cells. RL71 was the most potent curcumin analogue with EC50 values of 0.64 ± 0.04 and 0.38 ± 0.009 μM (n = 3) in D‐17 (commercial) and Gracie canine osteosarcoma cells, respectively. RL71 significantly increased the ratio of cleaved‐caspase 3 to pro‐caspase 3 and the level of apoptotic cells at the 2× and 5× EC50 concentration (p < 0.001, n = 3). Furthermore, at the same concentration, RL71 significantly increased the number of cells in the G2/M phase. In conclusion, RL71 has potent cytotoxic activity in canine osteosarcoma cells triggering G2/M arrest and apoptosis at concentrations achievable in vivo. Future research should further investigate molecular mechanisms for these changes in other canine osteosarcoma cell lines prior to in vivo investigation.Keywords
Funding Information
- University of Otago
This publication has 29 references indexed in Scilit:
- Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation studyPreventive Veterinary Medicine, 2016
- Evaluation of outcome and prognostic factors for dogs living greater than one year after diagnosis of osteosarcoma: 90 cases (1997–2008)Journal of the American Veterinary Medical Association, 2014
- Comparison of Carboplatin and Doxorubicin-Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular OsteosarcomaJournal of Veterinary Internal Medicine, 2014
- RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER-negative breast cancer modelsInternational Journal of Oncology, 2012
- RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cellsInternational Journal of Oncology, 2012
- Polymerase chain reaction–based species verification and microsatellite analysis for canine cell line validationJournal of Veterinary Diagnostic Investigation, 2011
- Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcuminBioorganic & Medicinal Chemistry, 2010
- Biological activities of curcumin and its analogues (Congeners) made by man and Mother NatureBiochemical Pharmacology, 2008
- Bioavailability of Curcumin: Problems and PromisesMolecular Pharmaceutics, 2007
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990